<DOC>
	<DOCNO>NCT00695279</DOCNO>
	<brief_summary>This protocol ( GENEFU ) provide mechanism 15-year followup period FDA require participant gene transfer protocols assures adequate followup maintain wide variety participant different individual gene therapy protocol St. Jude Children 's Research Hospital . GENEFU serve umbrella protocol long-term follow-up ( LTFU ) recipients gene therapy/gene mark ( GT/GM ) product St. Jude Children 's Research Hospital . The FDA recommend method ass risk delay adverse event GT/GM provide specific requirement regard duration design LTFU observation . This protocol intend provide LTFU accordance FDA guideline receive GT/GM product part St. Jude-sponsored clinical trial compassionate use treatment plan . The protocol call physical examination general health evaluation collection require blood sample annually 15 year last receipt GT/GM product . Goals obtain clinical history order detect late clinical outcome suggestive retroviral lentiviral disease , include limited cancer/second malignancy , neurologic disorder , autoimmune disorder , hematologic disorder . Blood sample archive test clinically scientifically indicate , event development second malignancy . This prospective cohort study utilize descriptive statistic analysis long-term late effect outcomes . It offer uniform approach long-term safety monitoring research participant receive gene-transduced product part St. Jude-sponsored GT GM protocol compassionate use treatment plan .</brief_summary>
	<brief_title>Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products</brief_title>
	<detailed_description>Secondary objective include follow : obtain archive blood sample 1 ) detect frequency vector mark peripheral blood mononuclear cell clinically scientifically indicate , event participant development second malignancy , autoimmune disease , hematologic abnormality , neurologic event , ; 2 ) To obtain archive blood sample detect characterize clonal proliferation event occur gene transfer trial clinically scientifically indicate .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<criteria>Has receive integrate retroviral lentiviral vector base GT/GM product St. Jude Children 's Research Hospital within past 15 year time period . Patient later 15 year post receipt GT/GM product .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Gene therapy</keyword>
</DOC>